Multiscale analyses reveal native-like lamellar bone repair and near perfect bone-contact with porous strontium-loaded bioactive glass by Autefage, H. et al.
Contents lists available at ScienceDirect
Biomaterials
journal homepage: www.elsevier.com/locate/biomaterials
Multiscale analyses reveal native-like lamellar bone repair and near perfect
bone-contact with porous strontium-loaded bioactive glass
H. Autefagea,b,c, F. Allend, H.M. Tanga, C. Kallepitisa,b,c, E. Gentlemane, N. Reznikova,b,c,
K. Nitiputria,b,c, A. Nommeots-Nomma, M.D. O'Donnella, C. Langef, B.M. Seidtf, T.B. Kima,
A.K. Solankia,b,c, F. Talliaa, G. Younga, P.D. Leea,g, B.F. Piercea,b,c, W. Wagermaierf, P. Fratzlf,
A. Goodshipd, J.R. Jonesa, G. Blunnd,h,∗∗, M.M. Stevensa,b,c,∗
a Department of Materials, Imperial College London, London, SW7 2AZ, United Kingdom
bDepartment of Bioengineering, Imperial College London, London, SW7 2AZ, United Kingdom
c Institute of Biomedical Engineering, Imperial College London, London, SW7 2AZ, United Kingdom
d Institute of Orthopaedics and Musculoskeletal Science, University College London, London, WC1E 6BT, United Kingdom
e Centre for Craniofacial and Regenerative Biology, King's College London, London, SE1 9RT, United Kingdom
fMax Planck Institute of Colloids and Interfaces, Department of Biomaterials, Research Campus Golm, Potsdam, Germany
gMechanical Engineering, University College London, Torrington Place, London, WC1E 7JE, United Kingdom
h School of Pharmacy and Biomedical Sciences, University of Portsmouth, PO1 2DT Portsmouth, United Kingdom
A R T I C L E I N F O
Keywords:






A B S T R A C T
The eﬃcient healing of critical-sized bone defects using synthetic biomaterial-based strategies is promising but
remains challenging as it requires the development of biomaterials that combine a 3D porous architecture and a
robust biological activity. Bioactive glasses (BGs) are attractive candidates as they stimulate a biological re-
sponse that favors osteogenesis and vascularization, but amorphous 3D porous BGs are diﬃcult to produce
because conventional compositions crystallize during processing. Here, we rationally designed a porous,
strontium-releasing, bioactive glass-based scaﬀold (pSrBG) whose composition was tailored to deliver strontium
and whose properties were optimized to retain an amorphous phase, induce tissue inﬁltration and encourage
bone formation. The hypothesis was that it would allow the repair of a critical-sized defect in an ovine model
with newly-formed bone exhibiting physiological matrix composition and structural architecture. Histological
and histomorphometric analyses combined with indentation testing showed pSrBG encouraged near perfect
bone-to-material contact and the formation of well-organized lamellar bone. Analysis of bone quality by a
combination of Raman spectral imaging, small-angle X-ray scattering, X-ray ﬂuorescence and focused ion beam-
scanning electron microscopy demonstrated that the repaired tissue was akin to that of normal, healthy bone,
and incorporated small amounts of strontium in the newly formed bone mineral. These data show the potential
of pSrBG to induce an eﬃcient repair of critical-sized bone defects and establish the importance of thorough
multi-scale characterization in assessing biomaterial outcomes in large animal models.
1. Introduction
Biomaterial-based approaches are an attractive alternative for the
repair of substantial bone defects that do not undergo full endogenous
repair and have given rise to a lucrative market in regenerative mate-
rials [1]. Synthetic inorganic materials including bioactive glasses
(BGs) and calcium phosphate ceramics [2–4] are particularly attractive
because they encourage bone bonding. BGs have the beneﬁt that they
can deliver active ions that alter cell responses and stimulate bone
regeneration [5–7]. The original BG composition (Bioglass® BG45S5)
has been used in more than a million patients as a synthetic particulate
bone substitute for the repair of small dental and osseous defects [2,8].
BG elicits a strong bone-to-material bond through the formation of a
carbonated apatite (HCA) layer on its surface. Moreover, as the material
degrades, it releases ions including calcium, phosphate, and soluble
silica species, which stimulate cellular responses such as bone forma-
tion and vascularization [5–7]. BG's compositional versatility also al-
lows for modulation of the material's characteristics, including its
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suitability for sintering and degradation proﬁle. Following reports de-
monstrating the eﬃcacy of the anti-osteoporosis drug strontium rane-
late (SrRan) [9,10], strontium has been incorporated into BG for bone
repair, as BG's amorphous nature allows it to deliver strontium at a
sustained rate. In in vitro studies, strontium-substituted BGs increased
the anabolic and anti-catabolic activity of osteoblasts and osteoclasts,
respectively [11–13], and strontium-substituted materials showed en-
hanced bone formation and osteointegration in vivo [14–20].
Despite such promising ﬁndings, studies describing bone repair
mediated by inorganic bone substitutes point towards the need for
three-dimensional (3D) porous structures and to elicit robust biological
activity. This is because an appropriate 3D architecture provides me-
chanical support and space for cell inﬁltration and neovascularization
prior to new bone formation [21]. However, while porous 3D scaﬀolds
based on 45S5 bioactive glass have been reported [22–29], 3D BG
porous scaﬀolds that retain the amorphous structure [30–32] have
proven more diﬃcult to produce because commercially available
compositions crystallize during sintering [24,25,27–29], disrupting
their ability to form the bone-bonding surface HCA layer and inhibiting
the release of cell-stimulating ions. To overcome these limitations and
explore the hypothesis that such design criteria will enhance the in-
growth of normal bone, we designed a strontium-containing BG
(pSrBG) by tailoring its composition, so that the glass would release a
therapeutic range of strontium and also possess a broadened sintering
window (temperature diﬀerence between the glass transition tem-
perature, which must be surpassed for sintering to occur, and the
crystallization onset temperature), making it possible to produce an
amorphous 3D porous scaﬀold. We then investigated its ability to re-
generate bone in a critical-sized defect in an ovine model [33], com-
paring its performance to the commercially available clinical standard
bioactive glass, BG45S5. We examined the quality of the newly-formed
bone using a combination of materials-based characterization techni-
ques including scanning electron microscopy (SEM) imaging of focused
ion beam-milled sections (FIB-SEM), small-angle X-ray scattering
(SAXS) and Raman spectroscopy. By analyzing the cell-material inter-
face and examining the newly-formed bone's biochemical signature and
structural organization, these techniques allowed us not only to reveal
the potential of pSrBG to generate high quality, locally-competent bone
but also highlighted the potential of detailed materials analyses in
understanding materials-driven bone repair.
2. Materials and methods
2.1. Material synthesis and processing
Glasses were made via the melt-quenching route. Silica (99.8%,
Tarmac Ltd. or High Purity, Prince Minerals, Stoke-on-Trent), calcium
carbonate (all≥ 98%, Sigma Aldrich, UK), magnesium oxide, sodium
carbonate, calcium phosphate, strontium carbonate and potassium
carbonate were mixed according to their molar percentage, melted
(1200–1400 °C) and quenched in deionized water to produce a frit. The
frit was dried at> 100 °C and was ground with a Jet Mill (Hosokawa
Micron Ltd. Runcorn, UK). Particles were sized by sieving.
BG45S5 (46.1 mol% SiO2, 24.4 mol% Na2O, 26.9 mol% CaO and
2.6 mol% P2O5) had particle size of 0.1–1mm.
For pSrBG processing, a glass composition of 44.5 mol% SiO2, 4 mol
% Na2O, 4mol% K2O, 4.5mol% P2O5, 17.8 mol% CaO, 17.8 mol% SrO,
7.5 mol% MgO was used and porous scaﬀolds were made as previously
described [34], with a glass slurry produced (using particles < 38 μm),
foamed with a surfactant and gelled by in situ polymerization [34]. The
polymer was then removed by thermal decomposition immediately
prior to sintering. Brieﬂy, the following process was used: 100 g of glass
powder and 30 g of the monomer methacrylamide (Fluka,> 98%) were
gently mixed and 15 g of the crosslinker N,N′-methylenebisacrylamide
(> 98%) was added under agitation. dH2O (90ml) was added to act as
the solvent and 10 drops of the dispersant Dispex were incorporated,
followed by 0.5 ml of Triton X-100 (surfactant). To start the poly-
merization reaction, 2ml of initiator (0.52 g/ml ammonium persul-
phate (> 98%) in dH2O), followed by 20ml of the catalyst TEMED
(N,N,N′,N′-Tetramethylethylenediamine, 99%) were added and the
system was vigorously agitated. Agitation was stopped immediately
prior to gelation and the gelled foam was dried (125 °C for 10 h). The
samples, cut into cubes, were then placed at 350 °C for 1 h, followed by
sintering for 3 h at 690 °C. These scaﬀolds were used for material
characterization by X-ray diﬀraction, X-ray ﬂuorescence (XRF), mer-
cury intrusion porosimetry and X-ray microtomography (μCT) analyses.
In vitro and in vivo studies were conducted on the material whose pro-
duction was up-scaled at a ratio 1:5. Instead of cutting the materials
into cubes, the resulting up-scaled sintered pSrBG scaﬀolds were then
ground using a Kek cone mixer (Kemutec, USA) to give granules of sizes
1–3mm.
2.2. In vitro cell culture experiments
Cytotoxicity measurements were performed according to the ISO-
10993-5 procedure, using MC3T3-E1 cells [35]. Liquid extracts from
pSrBG and BG45S5 (n=6) were obtained by incubating scaﬀolds in
alpha-Minimum Essential Medium Eagle (alpha-MEM, Gibco) at 0.2 g/
ml for 24 h at 37 °C. The extracts were passed through a 0.2 μm ﬁlter to
remove particle debris and placed at 37 °C in a 5% CO2 incubator
overnight. Extract media were supplemented with 5% (v/v) FBS, 50 μg/
ml ascorbic acid and 1% (v/v) penicillin/streptomycin (P/S). MC3T3-
E1 cells (ATCC) were seeded at 20,000 cells/cm2 and left to adhere for
24 h in complete growth medium (alpha-MEM + 5% (v/v)
FBS + 50 μg/ml ascorbic acid + 1% (v/v) P/S) prior to incubation with
the extract media for 24 or 72 h. Metabolic activity was measured by
AlamarBlue® assay (Life Technologies, UK) according to the manufac-
turer's instructions.
Bone marrow-derived human mesenchymal stem cells (hMSCs)
(Promocell GmbH) were expanded in Promocell hMSC growth medium
and used before passage 6. To evaluate the ability of primary osteo-
progenitors to grow on pSrBG scaﬀolds, 20,000 hMSCs were seeded on
pre-incubated (alpha-MEM for 24 h) scaﬀolds and cultured in growth
medium (alpha-MEM with 10% (v/v) FBS, 50 μg/ml ascorbic acid and
1% (v/v) penicillin/streptomycin (P/S). After 7 days, samples were
ﬁxed in 4% (v/v) paraformaldehyde/PBS for 15min and dehydrated
using a series of ethanol solutions, followed by incubation in hexam-
ethyldisilazane (Sigma). Samples were dried and sputter-coated with
Au before SEM imaging (Jeol 6010).
2.3. In vivo bone repair assessment
Non-pregnant skeletally mature female sheep at least two years old
were allocated randomly to treatment groups (1 defect per animal,
n≥ 5 per condition and time point). Additionally, three recently sa-
criﬁced sheep of the same criteria were used to prepare time zero
samples with surplus test materials. The work was supervised by G.
Blunn and A. Goodship and conducted under approval of and com-
pliance with the UK Home Oﬃce requirements, Animals (Scientiﬁc
Procedures) Act 1986, which included local ethical approval by the
Royal Veterinary College ethics committee.
One 8mm diameter cylindrical defect was made in the left medial
femoral condyle per animal, using an electric drill with a stop to limit
the defect depth to 15mm. As the critical defect nature of this model
has previously been assessed, to reduce the number of sacriﬁced ani-
mals, no empty defect control was performed in this study. The critical
nature of the defect, originated from a previous study [36], is clearly
shown in Fig. S1. For consistency, a ﬂat drill bit was used to ﬂatten the
bottom of the defect. The synthetic bone grafts were mixed with blood
from the defect on implantation (2:1 ratio of ovine blood to BG mate-
rial), allowed to coagulate, and the quantity necessary to ﬁll the defect
was inserted and compacted using a spatula. Kirschner wires were
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inserted adjacent to the defect for radiographic identiﬁcation. The an-
imals were not supported or immobilized after surgery. All animals
were checked for post-operative adverse eﬀects or local reactions to the
implants. Blood samples were collected at deﬁned time points and
strontium content was measured. The sheep were sacriﬁced at 6 weeks
or 12 weeks postoperatively with 0.7 ml/kg 20% intravenous pento-
barbital. The left medial condyles were retrieved using an oscillatory
saw.
Bone repair was assessed at 6 or 12 weeks postoperatively by per-
ipheral quantitative computed tomography (pQCT), indentation testing
(Zwick Roell Z005 H-frame compression-tensile loading machine using
a 4mm2 circular indenter), and histology and histomorphometry
(Toluidine Blue/Paragon staining). 200 μm thick sections of 12 week
samples were further prepared for SEM, high spatial resolution SAXS/
XRF, FIB-SEM of the interface between the newly deposited bone and
scaﬀolds and Raman spectral imaging. Contrast has been adjusted in
histology and SEM images for better visualization.
2.4. Small-angle X-ray scattering (SAXS) and X-ray ﬂuorescence (XRF)
Polished 200 μm sections of the resin embedded bone samples were
investigated with an environmental scanning electron microscope
(ESEM) (FEI-Company, Oregon, USA) in low vacuum using back-
scattered electron (BSE) mode at a working distance of 10mm. The
electron beam energy was set to be 10 kV. A solid state detector (SSD)
was used to measure the BSE signal from the sample surface.
For laboratory measurements (with low spatial resolution imaging),
SAXS equipment was used, based on an X-ray generator (Bruker, AXS,
Karlsruhe, Germany) with a rotating copper anode operating at 40 kV/
100mA, producing an X-ray beam with a wavelength of λ=0.154 nm.
The diameter of the beam at the sample was 200 μm and the sample
detector distance was 620mm [37].
The bone sections were mounted on a sample holder which could be
moved automatically with a precision of 2 μm in the plane perpendi-
cular to the incident beam. Data were collected with an area detector
(Bruker) and corrected for background scattering. Prior to the scat-
tering measurements an X-ray transmission image of the bone sample
was produced by measuring the X-ray absorption of the sample using a
diode to determine the positions for the SAXS experiments. After the
SAXS measurement, scattering patterns were obtained representing the
intensity distribution scattered around the primary beam which was
transmitted through the bone sample for 1 h. The two-dimensional
SAXS patterns were analyzed for mean mineral crystal thickness (T-
parameter) and the degree of alignment of the mineral crystals (ρ-
parameter) within each sample. High spatial resolution measurements
were carried out at the synchrotron beam line μSpot at BESSY II
(Helmholtz-Zentrum Berlin für Materialien und Energie, Germany).
Synchrotron radiation was used to measure SAXS and the X-ray ﬂuor-
escence (XRF) of calcium and strontium simultaneously with a beam
diameter of 30 μm [38]. The sample to detector distance was 313mm
and the wavelength of the X-ray beam was 0.06888 nm. Calcium and
strontium distribution maps were created using the XRF signal to deﬁne
the regions of interest for the measurements. An energy sensitive de-
tector (ASAS-SDD KETEK, Munich, Germany) with a 100-mm2 sensitive
active area and 167.4 eV energy resolution was used for the XRF
measurements, allowing for the determination of variations in stron-
tium and calcium contents.
2.5. Focused ion beam-scanning electron microscopy
Cross-sections of trabecular bone tissue at the interface between the
newly deposited bone and BG45S5 or pSrBG samples were prepared
and imaged using a FEI Helios 600 Dual Beam system as follows.
Samples were demineralized (in 0.5M EDTA, 2% (v/v) PFA, CaCo, pH
7), stained with alcian blue (for proteoglycan stabilization), post-ﬁxed
with 4% (v/v) glutaraldehyde, stained with osmium tetroxide and
thiocarbohydrazide (conductive staining) and sputter-coated with Au.
Areas of interest were coated with a protective 0.5–1.0 μmPt layer in
two steps at the ion current 0.28 nA ﬁrst and then 0.92 nA. Ion milling
of cross-sections ∼60 μm wide and ∼20 μm deep were performed at
30 keV with a gradual reduction of the milling current from 21 nA to
2.8 nA. Imaging was performed using mixed secondary-back-scattered
electron detection. Each tiled cross-section spans an area of about
50× 12 μm (with 10 nm pixel size) and comprises between 6 and 18
partly overlapping frames. The orientation of each cross-section is
perpendicular to the bone/grain boundary. Results are representative of
≥2 bone-material interface cross-sections from 3 independent sections
per material-treated defect at 12 weeks.
2.6. Raman spectral imaging
For Raman spectral imaging a confocal Raman micro-spectroscope
(alpha300R+, WITec, Ulm, Germany) was used. All experiments were
performed using a 532 nm laser and a 10 × /0.3 NA microscope ob-
jective lens. Raman spectral images of∼800 × 800 μm were produced
with 2 μm spatial resolution at 0.5 s integration time and spectral range
0–3000 cm−1. The Control FOUR software was used for all data col-
lection.
The procedure carried out on each dataset included a baseline
correction, smoothing (Savitzky-Golay) and normalization. K-means
clustering was used to spectrally identify the diﬀerent regions within
the samples. The selected bone characterization parameters were cal-
culated using the integrated areas of selected bands. For the mineral-to-
matrix ratio (MMR) the∼960 cm−1 phosphate band was divided by the
sum of the ∼854 cm−1 and ∼871 cm−1 proline and hydroxyproline
bands. The mineral-to-carbonate ratio (MCR) was calculated using the
∼960 cm−1 phosphate band divided by the ∼1070 cm−1 carbonate
band. For the mineral crystallinity the FWHM of the ∼960 cm−1
phosphate band was used [39]. The Project FOUR Plus software was
used for all data processing. All spectra presented were intensity cali-
brated according to the National Institute Standard and Technology
(NIST) material. Results are representative of ≥2 Raman spectral
images from 3 independent sections of pSrBG- or BG45S5-treated defect
at 12 weeks.
2.7. Statistical analysis
Statistical analyses were carried out using 2-way ANOVA analysis
with a Bonferroni post-hoc test to compare the treatment groups and
time points, unless stated otherwise. Diﬀerences with p-values lower
than 0.05 were considered signiﬁcant.
Details of the materials characterization, in vivo explant preparation
and analyses, and SAXS parameter calculations are provided in the SI
experimental procedures.
3. Results
3.1. pSrBG is a non-toxic, strontium-containing, amorphous, highly porous
BG
We have previously shown that other compositions of strontium-
substituted BG upregulate osteoblast activity and downregulate osteo-
clast activity in vitro [11]. Moreover, using whole-genome microarray
analysis, we showed that strontium-containing BG modulated human
mesenchymal stem cells' (hMSCs) metabolic activity and triggered
modiﬁcations in membrane composition [40]. Based on these results,
we aimed to design a porous 3D BG scaﬀold that would allow a release
of strontium ions in similar concentrations. Successfully formulating a
3D porous BG scaﬀold while preserving its amorphous phase, however,
required us to ﬁnely tune its composition and processing parameters.
Optimizing the composition was particularly critical, as it both deﬁnes
the BG's biological activity and aﬀords the material appropriate
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processing characteristics such as a wide sintering window. Using 45S5
composition as a basis for our design, the number of network modiﬁers
(K+ and Mg2+), and the SiO2 content were slightly increased in order to
broaden the sintering window. The total cation content with +1 charge
was also reduced from 24.4 mol% Na2O in 45S5 to 12mol% in pSrBG
(6mol% Na2O and 6mol% K2O), to reduce initial rate of cation ex-
change and limit the increase in pH when scaﬀolds are immersed in
ﬂuid (Fig S2A). Strontium was included to reduce the relatively high
Ca2+ content (35.6 mol%), and to play the role of a therapeutic agent as
well as acting as another network modiﬁer to further expand the sin-
tering window. We determined that with 50mol% of Ca2+ substituted
by Sr2+, strontium ions were released in vitro at mM range concentra-
tion (Figs S2E and S3A) that is known to be susceptible to aﬀect hMSC
responses to BG in vitro [40]. Our optimized composition, which has
been seen investigated with regards to dissolution and phase formation
in aqueous solutions in vitro [41], consisted of 44.5 mol% SiO2, 4 mol%
Na2O, 4mol% K2O, 4.5mol% P2O5, 17.8 mol% CaO, 17.8 mol% SrO,
7.5 mol% MgO (Fig. 1A and Table S1). We utilized a gel-cast foaming
process, employing a combination of vigorous agitation in the presence
of a surfactant and in situ polymerization [34] to create and maintain a
porous structure. As anticipated, the pSrBG composition broadened the
sintering window (174 °C compared to < 100 °C for BG45S5 [34]),
allowing us to generate a BG that retained an amorphous phase: X-ray
diﬀraction conﬁrmed that, with the exception of a very small peak that
could not be identiﬁed, sintered pSrBG scaﬀolds were predominantly
composed of an amorphous phase (Fig. 1A; BG45S5 XRD pattern is
shown for reference in Fig S4A). There was concern that the water
based gel-cast foaming process may promote early onset crystallization
at the particle surface, as seen in previous work foaming the ICIE 16
composition (49.46% SiO2, 36.27% CaO, 6.6% Na2O, 1.07% P2O5 and
6.6% K2O, in mol%) [34], but the XRD pattern (Fig. 1A) showed that
this was not the case for pSrBG. MicroCT analyses showed that pSrBG
had a homogeneous distribution of highly interconnected pores
(Fig. 1B–E) that were likely suitable for cell inﬁltration, bone formation
and vascularization [21]. We measured>3 interconnects per pore, a
modal pore size> 400 μm, and a modal interconnect size> 100 μm
(Fig. 1B). Mercury porosimetry measurements (Fig. 1B) and SEM on
pSrBG cross-sections (Fig. S4B) further supported the presence of in-
terconnects within the scaﬀold. Taken together, these results conﬁrmed
that pSrBG had many ideal physical properties for promoting bone re-
pair.
To conﬁrm that our designed composition would not elicit an acute
cytotoxic response, we placed extracts containing ions dissolved from
the material on mouse MC3T3-E1 cells, according to ISO-10993-5 (Fig.
S3A–B). We saw no signiﬁcant diﬀerences in cell metabolic activity
between cells treated with pSrBG and BG45S5, conﬁrming that pSrBG
composition performed at least as well as standard BGs. Moreover,
when hMSCs were seeded directly onto pSrBG, SEM images showed
cells attached to the scaﬀold's inner and outer surfaces (Fig. S3C–D),
suggesting that pSrBG was not only non-toxic, but could also support
cell invasion and growth.
3.2. pSrBG is highly osteoconductive and encourages an eﬀective bone
repair
As our in vitro characterizations suggested that pSrBG was a good
Fig. 1. pSrBG is a strontium-containing BG and displays highly interconnected pores. (A) X-ray diﬀraction showing that pSrBG retains an amorphous phase and
pSrBG composition, expressed in mol%. (B) Interconnect (solid black line) and pore (dotted black line) diameter distribution (measured by μCT), and interconnect
diameter distribution measured by mercury porosity (dashed blue line). (C–E) μCT reconstruction of pSrBG scaﬀold showing (C) the whole scaﬀold, (D) the pores and
(E) interconnects within the scaﬀold. Scale bars= 500 μm.
H. Autefage, et al. Biomaterials 209 (2019) 152–162
155
candidate for bone repair, we evaluated its ability to repair bone in vivo.
To our knowledge, no study has yet evaluated the eﬃcacy of a stron-
tium-containing 3D porous bioactive glass to repair a critical-sized bone
defect in a large animal model. We implanted pSrBG scaﬀolds, in the
form of 1–3mm granules, into critical-sized femoral condyle defects in
sheep (drill hole, 8 mm diameter x 15mm depth) and evaluated bone
formation after 6 and 12 weeks. To assess the performances of our
pSrBG scaﬀold in an in vivo pre-clinical setting, as a control, we used
BG45S5 particles (0.1–1mm), a commercially available, clinical stan-
dard BG product that cannot be formulated as a 3D amorphous scaﬀold
due to its crystallization during sintering.
We observed no adverse post-operative eﬀects or local reactions to
the implants. Initial histomorphometry analyses showed that after 6
weeks, both pSrBG and BG45S5 scaﬀolds allowed for bone growth into
the defect. The percentage of newly deposited bone in both groups was
consistent with that in normal femoral trabecular bone, measured in
control areas away from the defect zones, with median values of 43%,
40%, and 42% for pSrBG, BG45S5, and control areas of normal trabe-
cular bone, respectively. 12 weeks post-operatively, these values re-
mained stable and we found no statistical diﬀerences at either of the
time points we examined (Fig. 2A and Fig. S5A), conﬁrming previous
reports of the eﬃcacy of BGs in promoting bone repair [6]. However,
despite these similarities, pSrBG signiﬁcantly outperformed BG45S5 in
terms of scaﬀold bone coverage (p < 0.05 at 6 weeks). pSrBG scaﬀolds
were remarkably 99% and 100% covered with new bone at 6 and 12
weeks (Fig. 2B), respectively, including internal pore walls. BG45S5, on
the other hand, only showed 86% and 91% coverage, respectively.
Moreover, while pSrBG-treated defects showed similar inﬁltration by
soft tissue (i.e. bone marrow and blood vessels, 33%) when compared to
the surrounding trabecular bone (58%) (Fig. S5B), BG45S5-treated
defects were signiﬁcantly more densely packed with bone and re-
maining synthetic material (14% soft tissue at 12 weeks, p < 0.05).
This ﬁnding suggested a beneﬁcial eﬀect of pSrBG porous architecture
on the structure of the newly formed bone, which was found to be more
akin to normal trabecular bone in pSrBG-treated defects than that in
defects treated with BG45S5.
As BG45S5-treated defects were more densely packed than those
treated with pSrBG, we hypothesized that the BG45S5 repair tissue
would be stiﬀer. To assess this, we performed indentation testing.
Although the stiﬀness of the repaired tissue in both groups increased
between 6 and 12 weeks, we could not detect signiﬁcant diﬀerences
between them and both were comparable to control regions of normal
trabecular bone (Fig. 2C). This was particularly surprising as pSrBG-
treated defects had less remaining implant material in the defect site
than BG45S5-treated defects (p < 0.01 at both time points) (Fig. S5C).
Thus the repair in pSrBG was mediated by a signiﬁcantly higher newly
formed bone-to-scaﬀold ratio than that in BG45S5 (Fig. 2D). Taken
together, these data suggest that while BG45S5 formed a dense repair
tissue supported by stable synthetic material, pSrBG elicited the for-
mation of trabecular bone with strength, density and a soft tissue
composition similar to that of normal bone. In short, pSrBG was highly
osteoconductive and promoted an eﬀective repair with local properties
similar to that of native trabecular bone.
3.3. pSrBG promotes the formation of well-organized lamellar neo-bone
tissue
We also carried out histological analyses to macroscopically
Fig. 2. pSrBG shows enhanced osteoconductive properties and induces the formation of well-organized locally competent lamellar bone tissue. (A) Percentage of
newly formed bone in defects treated with BG45S5 particles or pSrBG granules for 6 weeks and 12 weeks. The dashed line represents the median of the percentage of
bone in non-defect areas (n=19). (B) Percentage of bone that contacts the remaining scaﬀold. (C) Local mechanical assessment of the defect sites performed by
indentation testing. The dashed line represents the stiﬀness median of the control trabecular bone in BG45S5-treated animals at 12 weeks (n= 5). (D) Ratio of newly-
formed bone to the remaining scaﬀold. The box plots represent the 5th to 95th percentiles. Asterisks denote statistically signiﬁcant diﬀerences between indicated
groups (*p < 0.05, **p < 0.01, ***p < 0.001). In (A, B and D), at 6 weeks n=5 and at 12 weeks n=6, in (C) n=6 for both time points. (E–H) Histological
examination after 6 weeks of implantation of BG45S5 (E, F) and pSrBG (G, H). (I–L) Histological examination after 12 weeks of implantation of BG45S5 (I, J) and
pSrBG (K, L). Histology sections were stained with Toluidine Blue and Paragon. Arrows point at the remaining synthetic materials; b represents new formed bone; bm
represents bone marrow; f represents ﬁbrous tissue. Scale bars in E, G, I, K are 300 μm; scale bars in F, H, J, L are 60 μm. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the Web version of this article.)
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characterize the newly-formed bone in the defects (Fig. 2E–L). Our
analyses conﬁrmed the presence of new bone in both pSrBG- and
BG45S5-treated defects, marked by the presence of osteocytes, lacunae,
bone marrow, and blood vessels. Such features were present 6 weeks
after implantation and were more abundant after 12 weeks. Never-
theless, diﬀerences between the BG45S5 and pSrBG scaﬀolds were
again apparent. We corroborated our exciting previous observation of
100% bone-to-material contact, characterized by a complete lack of
ﬁbrous tissue coverage (Fig. 2 G, H, K, L) on pSrBG scaﬀolds only 6
weeks after implantation, while at this time point, ﬁbrous tissue could
clearly be observed adherent to the surface of BG45S5 (Fig. 2F).
Moreover, whereas overall, defects treated with BG45S5 were compact
and composed of newly-formed bone surrounding randomly-dispersed
glass particles (Fig. 2 E, F, I, J), pSrBG-treated defects contained well-
organized lamellar bone characterized by bone marrow and blood
vessels within scaﬀold pores (Fig. 2 G, H, K, L). These histology ob-
servations suggested that, while the possibility of being partly aﬀected
by the grafts' arrangement within the defects during implantation ex-
isted, the diﬀerences in histomorphometry parameters found between
pSrBG and BG45S5 were primarily the result of the materials’ physico-
chemical characteristics (i.e. porous architecture and composition).
SEM backscattering images conﬁrmed histology ﬁndings and
showed mineralization of the newly-formed bone tissue (Fig. S6). These
data demonstrate pSrBG's ability to promote robust bone formation,
and importantly, bone formation directly at the implant surface.
3.4. pSrBG promotes deposition of lamellar neo-bone at the bone/material
interface by 12 weeks
These promising results from our histological analyses encouraged
us to gain further insight into the quality of the repaired tissue and the
bone/material interface. Therefore, we next examined bone quality,
using a powerful combination of techniques. As bone mineral is tem-
plated on collagen, we examined collagen organization in the treated
defects. We demineralized sections and utilized a powerful technique
based on focused ion beam milling combined with scanning electron
microscopy (FIB-SEM) to image the interface between the scaﬀold and
newly formed tissue (Fig. 3) [42,43]. Sections from both the pSrBG- and
45S5BG-bone interface contained abundant collagen ﬁbrils (recogniz-
able by their D-periodicity), lacunae connected by canaliculi, and
fragments of shrunken osteocyte vestiges. However, diﬀerent features
were observed in the newly-formed bone adjacent to pSrBG when
compared to BG45S5. In BG45S5-treated defects, we often observed
a<1 μm thick, intensely stained interface between the bone and im-
plant, indicative of non-collagenous organic material between the im-
plant and the newly-formed bone (Fig. 3A). We observed no such well-
deﬁned interface in pSrBG-treated defects. This tissue contained
spindle-shaped osteocyte lacunae surrounded by electron-dense halos
and alternating ∼3 μm thick lamellar bundles - features indicative of a
canonical lamellar structure [42,43] (Fig. 3B). Conversely, at the in-
terface with BG45S5, we observed irregularly-shaped osteocyte lacunae
and a collagenous matrix containing 2–3 μm thick bundles of ﬁbers with
random orientations (Fig. 3A). This woven bone-like layer was deli-
mitated from adjacent lamellar bone by an intensely stained sub-μm-
thick line characteristic of a ‘cement line’: a ubiquitous ﬁnding at in-
terfaces between old and new bone [44]. Quantitative analyses of
several cross-sections (≥2 FIB-milled cross-sections from 3 independent
samples per condition) showed that tissue adjacent to BG45S5 was
composed of∼49% woven bone, while 81% of the bone at the interface
with pSrBG was lamellar (Fig. 3C, Table S2). In short, this micro-scale
FIB-SEM analysis of the bone/material interface allowed us to uncover
that while the BG45S5-bone interface was composed of both lamellar
and woven bone, indicative of tissue repair, the bone-material interface
mediated by pSrBG was almost exclusively lamellar as is found in
normal, functional bone tissue, suggesting possible diﬀerences in bone
formation or remodeling mechanism between the scaﬀolds.
3.5. pSrBG promotes native-like mineral nano-scale crystal characteristics
in neo-bone
Studies in the 1930s indicated that animals fed large amounts of
strontium developed a condition called ‘strontium rickets’ [45], which
was characterized by abnormal bone mineralization. Although re-eva-
luation of these studies now attributes poor mineralization to calcium
deﬁciency rather than strontium toxicity, concerns remain that repla-
cing calcium with the larger strontium atom in the bone apatite lattice
could produce mineralization defects. To examine this possibility, we
performed SAXS measurements on sections taken from defects sites 12
weeks after implantation [46,47]. We measured ρ- (mineral crystal
alignment) and T- (average thickness of the mineral crystals) para-
meters and found no signiﬁcant diﬀerences between them (Fig. 4 and
S7) indicating that strontium in the pSrBG scaﬀold did not appear to
aﬀect bone apatite crystal characteristics at the nano-scale. Interest-
ingly, when we compared regions of interest in our treated defects to
control regions for both samples, we found the T-parameter to be lower
in the newly formed bone (the ρ-parameter was not signiﬁcantly dif-
ferent) (Fig. 4 and S7), where mineral deposition was still ongoing.
3.6. pSrBG-released strontium incorporates exclusively in the neo-bone
While we could not detect an impact of strontium in pSrBG-treated
groups on bone apatite crystal characteristics, we did ﬁnd it in the
Fig. 3. FIB-SEM investigations reveal
that pSrBG promotes lamellar neo-bone
at the bone/material interface at 12
weeks. (A-B) Broad cross-sections (com-
pound images) through the interface be-
tween the implant particle on the right hand
side and the newly deposited bone. (A)
BG45S5 sample cross-section shows a broad
intensively stained scalloped boundary
(arrow head) that separates the particles
from bone containing chaotically oriented
bundles. An irregularly shaped osteocyte
lacuna can be observed in this region (#).
Another interface (arrow) separates this
presumably woven bone from parallel ar-
rays of collagen, characteristic for lamellar
bone. In pSrBG (B), collagen ﬁbrils are deposited directly on the granule surface with no obvious non-collagenous interface. To the left of the osteocyte lacuna (#)
bone matrix is organized in lamellar layers. Asterisks represent remaining inorganic materials. Graphics are inserted to facilitate visualization. (C) Percentage of
woven and lamellar bone at the material interface in ion-milled cross-sections from three pSrBG- and BG45S5-treated defect samples (2 or 3 cross-sections per
sample). The reader is invited to refer to Table S2 for more detailed information regarding the distribution within each sample. Scale bars are 5 μm.
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animals' plasma up to day 21 (Fig. 4E), demonstrating that it was ef-
fectively released from the scaﬀolds for a sustained period of time.
Nevertheless, the level of strontium we detected in the animals’ plasma
was 40-fold lower than that measured in the plasma of patients treated
with SrRan (0.12 mM), indicating that strontium can be released from a
biomaterial without producing systemic eﬀects [9]. Supporting this
ﬁnding, pQCT analyses of the pSrBG-treated defects showed a decrease
in density at 6 weeks, consistent with the loss of strontium from the
scaﬀold (strontium has a higher X-ray density than calcium) [48] (Fig.
S8). When we evaluated the spatial distribution of strontium in newly
formed bone in pSrBG-treated defects by XRF, we found it co-localized
with calcium, but absent from both control regions away from the
defect (Fig. 4C) and BG45S5-treated defects (Fig. 4D). This ﬁnding
conﬁrms previous studies in SrRan-treated patients, which show that
strontium incorporated only into newly formed bone [46]. XRF maps
also highlighted that strontium remained in the pSrBG, suggesting that
although strontium was released, the scaﬀolds remain a reservoir for
potential further release.
3.7. pSrBG promotes neo-bone with a native-like biochemical signature
We next examined if strontium's presence in the BG impacted es-
tablished spectroscopic measurements of bone quality [39,49]. We
carried out Raman spectral imaging on samples 12 weeks after
Fig. 4. pSrBG-released strontium incorporates into the neo-bone exclusively and promotes native-like bone mineral crystal thickness. (A–B) ESEM image of
(A) pSrBG- and (B) BG45S5- treated defect at 12 weeks showing the regions of interest (ROI) and control (CTL). (C–D) SAXS measurement of T-parameter (left) and
XRF reading (right), showing the localization of strontium and calcium ions, in the defects treated with (C) pSrBG and (D) BG45S5. Scale bars in (A, B) are 1mm;
scale bars in (C, D) are 250 μm for T-parameter (left) and 200 μm for XRF reading (right). (E) Serum strontium concentration measured in the blood of the animals
over 90 days. Data are expressed as mean ± SD. Asterisks denote statistically signiﬁcant diﬀerences between indicated conditions (**p < 0.01, ***p < 0.001) as
found by performing a Dunnett's Multiple Comparison Test with t=0 as control (n=12).
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implantation and used unsupervised classiﬁcation analysis techniques
to probe for changes in bone quality (Fig. 5). A k-means clustering
analysis of Raman spectra collected from both BG45S5- and pSrBG-
treated defects identiﬁed groups indicative of: (i) soft tissue, (ii) newly-
formed bone, and (iii) synthetic material modiﬁed following contact
with biological ﬂuids [50] (Fig. 5A–C and S9A-D). This observation
conﬁrmed previous studies that show the presence of an interfacial
region between BG and surrounding tissue through the precipitation of
HCA [2,8], and is in line with the kinetics of dissolution/precipitation
observed during immersion in simulated body ﬂuid (SBF), indicating
that both BG45S5 and pSrBG follow a similar mechanism of HCA for-
mation to the one described by Hench (Fig. S2 and [51]). Interestingly,
the Raman data further showed the inner portion of remaining large
BG45S5 particles produced an additional cluster (iv) characteristic of
the material as initially produced [50], while this feature was not ob-
served in pSrBG-treated defects. The newly-formed bone in both
BG45S5- and pSrBG-treated defects produced a single cluster with
comparable quality, as measured by mineral-to-matrix ratio (MMR),
carbonate-to-mineral peak ratio (CMR), and full width half maximum
(FWHM) (Fig. 5D and E), indicating that there were no detectable dif-
ferences in the bones' biochemical composition between the two
treatments. Moreover, for both treatments, no statistical diﬀerences in
these bone quality parameters, with the exception of FWHM (higher in
both treatment groups vs. control), were found between the newly-
formed bone and control region (Fig. S9) [39,52]. FWHM is often used
as a measurement of bone crystallinity and lower FWHM is associated
with aged bone. Therefore, these data suggest that the strontium in
pSrBG had little eﬀect on the quality of newly formed bone, and the
only diﬀerences we could detect could be attributable to the abundance
of newly formed, relatively immature bone in the pSrBG-treated de-
fects.
4. Discussion
Here we developed a 3D porous strontium-containing BG using a
gel-cast foaming method on an optimized BG composition. This process
allowed for the formation of a porous BG with homogenously dis-
tributed, interconnected pores optimized for bone in-growth and blood
vessel formation [21]. Gel-cast foaming requires sintering, which in the
past often resulted in BG crystallization due to a small sintering
window. Our optimized composition enlarged the sintering window
and facilitated the material's design as a 3D porous scaﬀold that re-
tained an amorphous phase, a feature that cannot be achieved using
conventional BGs such as 45S5. To enhance its biological activity, we
added strontium to harness its therapeutic properties [9,10]. Although
strontium's mechanism of action remains unknown, strontium-con-
taining inorganic bone substitutes increase bone formation and os-
teointegration in vivo [14–20], and modulate the activity of osteopro-
genitors, osteoblasts, and osteoclasts, and macrophage phenotype in
vitro [11,12,53–56]. We have recently shown using a whole-genome
microarray analysis that strontium incorporation in BG45S5 triggered
signiﬁcant changes in the global gene expression patterns of hMSCs and
resulted in important changes in their metabolism and membrane
composition [40]. Based on that evidence, we expected the incorpora-
tion of strontium into pSrBG to have a positive impact on the bioactive
glass's osteoconductive potential. pSrBG also released other ions that
have been shown to modulate cell responses, such as magnesium or
silicate species (Fig. S2). Together with strontium, those ions would be
expected to inﬂuence the material's biological activity and, as a result,
bone formation [57,58]. Overall, pSrBG presents good biomaterial
candidacy as it shows: (i) a 3D morphology with homogeneous pores of
optimal size; (ii) an amorphous structure, essential for surface inter-
actions and ion release; (iii) good in vitro biocompatibility; and (iv)
Fig. 5. pSrBG promotes neo-bone with a native-like biochemical signature. Raman spectral imaging of (B, D) BG45S5- and (C, E) pSrBG- treated defects at 12
weeks. (A) Characteristic Raman spectral signatures, identiﬁed by k-means clustering analysis, representing the (i) soft tissue, (ii) bone, and (iii) synthetic material
after modiﬁcation in contact with biological ﬂuids and (iv) synthetic material with similar characteristics to non-implanted BG45S5. As produced, pSrBG and BG45S5
are shown for reference (black lines). Spectroscopic BG modiﬁcations following implantation include a decrease in intensity of the bands attributed to the Si-O-Si
groups (∼560-620 cm−1, 857 cm−1, 1000-1200 cm−1), a shift of the phosphate ν1P-O peak from ∼945 to ∼960 cm−1 and an increase of the ν2P-O band at
∼430 cm−1 (highlighted in grey). (B-C) Distribution of the characteristic spectra identiﬁed by k-means clustering analysis. (D-E) Heat maps (a.u.) of the 960 cm−1
and 945 cm−1 peaks, mineral-to-matrix ratio (MMR) (obtained by dividing the 960 cm−1 band and the sum of the ∼854 cm−1 and ∼871 cm−1 proline and
hydroxyproline bands), carbonate-to-mineral ratio (CMR) (obtained by dividing the ν1CO32− band at 1070 cm−1 and the 960 cm−1 band) and, mineral crystallinity
(1/full width half maximum (1/FWHM) of the 960 cm−1 peak). Scale bars are 100 μm.
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strontium release, which can regulate osteoprogenitor biological ac-
tivity.
While most functional studies focusing on evaluating the properties
of strontium-containing bone substitutes are performed on rodents, we
used a large animal model that reﬂects more of the human clinical si-
tuation. We evaluated the ability of pSrBG to regenerate bone in a
critical-sized defect in an ovine model and compared it to the perfor-
mance of the commercially available and clinical BG standard BG45S5.
Histological and histomorphometry analyses showed that the amount of
newly-deposited bone in defects was comparable between pSrBG,
BG45S5 and normal healthy trabecular bone as early as 6 weeks post-
implantation. Measurements of defect stiﬀness further showed that the
newly-formed bone in both groups possessed similar local mechanical
properties to that of control regions of trabecular bone. However, while
ﬁbrous tissue was present at the implant surface in BG45S5-treated
defects, a result that was expected after only 6 weeks of implantation of
a bone substitute, we remarkably observed near 100% bone contact
with pSrBG, characterized by a quasi-total absence of ﬁbrous tissue at
the interface with pSrBG. Other synthetic bone substitutes do not
usually elicit such a high percentage of bone-material contact in such a
short period of time post-implantation. This result not only demon-
strated that pSrBG's osteoconductive properties signiﬁcantly out-
performed those of BG45S5, but also raises the intriguing question
whether such diﬀerences in newly-deposited tissue characteristics may
be the result of the scaﬀold's inﬂuence on the bone regeneration/re-
modeling kinetics or mode of action.
Dissolution kinetics in SBF or buﬀers (e.g. Tris buﬀer) can provide
important information to better characterize how the partial dissolution
of the BG might change the implant local microenvironment with re-
gards to ionic concentration and pH, and to assess the materials' ability
to form an HCA layer at this surface [32,59,60]. Incubation of pSrBG
and BG45S5 in SBF triggered, as expected, an initial quick release of
cations and phosphate, followed by a decrease in calcium and phos-
phate contents from the SBF for both materials (Fig. S2). Those ob-
servations are in accordance with the mechanism of HCA formation
described by Hench [51]. Interestingly, however, the rate of decrease of
calcium and phosphate ions was higher when BG45S5 was immersed in
the SBF than for pSrBG. This suggested the formation of HCA on
BG45S5's surface was quicker than on pSrBG samples. As the cation
release and the calcium phosphate deposition was more rapid for the
BG45S5 powder compared to pSrBG powder of similar particle size, the
diﬀerence in behavior was attributed to the glass composition rather
than the morphology (Fig. S2). The materials' eﬃciency in forming the
HCA layer at their surface is sometimes deemed to be correlated to the
in vivo outcome of calcium phosphate-containing materials. While our
ﬁndings indicated that both BGs have the potential to form an HCA
layer at their surface layer, they did not show a direct correlation be-
tween the HCA formation and the in vivo higher bone-to-material con-
tact observed in pSrBG samples.
We aimed to further assess the bone/material interface and char-
acterize the newly-formed bone quality. Most studies investigating bone
substitute performances focus on bone quantity and histomorphometry
parameters but fail to account for the quality of the repaired tissue.
However, in-depth assessment of bone quality has been demonstrated
to be highly relevant for the characterization and investigation of bone
pathologies and would largely beneﬁt the bone tissue engineering/
biomaterial community. The quality of bone tissue is dependent on a
number of parameters including its macrostructure, collagen organi-
zation, degree of mineralization, and crystallinity. Raman spectral
imaging, SAXS and FIB-SEM reconstruction are state-of-the-art techni-
ques that have recently emerged as important tools to characterize
normal and pathological bone quality [39,43,46,52]. Together, they
allowed us to examine the structural organization of the newly formed
bone, the bone-material interface, and the eﬀect of strontium on bone
biochemical and mineral characteristics. Our results show that pSrBG
elicited the formation of more mature-like lamellar bone, similar to that
in normal trabecular bone [61], when compared to that formed in
BG45S5-treated defects. Moreover, as shown by FIB-SEM, newly-
formed bone was in direct contact with pSrBG and possessed a lamellar
organization. The bone-BG45S interface, on the other hand, was com-
posed of both woven- and lamellar-like bone, which were delimited by
a cement line, a feature of the classical bone remodeling process fol-
lowing repair [44]. These observations are enticing as they suggest that
pSrBG, unlike BG45S5, may directly trigger the formation of well-or-
ganized lamellar bone.
When we evaluated the newly-formed bone in contact with pSrBG
by Raman spectroscopy, we could detect no diﬀerences in markers of
mineralization and bone maturity compared to healthy bone [39,49],
other than a higher FWHM (indicative of lower crystallinity). Although
these biochemical signatures are consistent with younger bone, such
changes have also been described following strontium incorporation
within the apatite lattice [62,63]. We carried out SAXS analysis to ex-
amine this possibility and detected a decrease in the average thickness
of the bone mineral crystals and mineral crystal alignment when
compared to control regions. However, we observed similar decreases
in BG45S5-treated defects, suggesting that these observations are likely
attributable to the relative bone tissue age [47] rather than the presence
of strontium [46].
Our XRF analyses demonstrated the presence of strontium in newly-
formed bone and in remaining material, but not in trabecular bone
adjacent to the defect. These ﬁndings are consistent with those obtained
from bone biopsies of SrRan patients and likely reﬂect the incorporation
of strontium into bone apatite via substitution for calcium ions during
bone formation [46,64,65]. The release of ions from pSrBG was further
conﬁrmed by pQCT analysis and the presence of strontium in the blood
of the animals. Dissolution extracts from strontium-containing BGs have
previously been shown to induce hemolysis in vitro at high concentra-
tion (> 250mg/ml) while lower concentrations did not trigger a sig-
niﬁcant hemolysis of red blood cells [52]. While the local concentration
of strontium that can be reached at the implant site still remains un-
known, we did not observe any adverse eﬀects of pSrBG implantation
on the animal health and as strontium was only detected in the circu-
lating blood for 21 days following implantation and with a maximum
concentration 40 times lower than that measured in the plasma of
SrRan patients [43], the risk of potential systemic eﬀects appears low.
However, importantly, this also suggests that, locally, the change in
ionic environment, including the presence of strontium, may be sus-
tained for a period of time suﬃcient to trigger speciﬁc biological re-
sponses.
In conclusion, our study describes the potential of pSrBG to repair
critical-sized bone defects and is an attractive alternative to autologous
bone transplantations. There is a growing interest in synthetic inorganic
porous scaﬀolds for bone repair. For example, clinical trials for spinal
fusion have been recently published for Actifuse®, a granular silicon-
containing porous hydroxyapatite. However, while promising, such
studies show the challenge of producing inorganic scaﬀolds that can
eﬀectively compete with current clinical standards [66]. Here, our
design of pSrBG fulﬁlls many requirements [2] as it allows for cell in-
growth and matrix deposition while ensuring mechanical support and
progressive degradation as new bone forms. When implanted in the
same animal model that we used here, Actifuse® elicited a ‘medium-to-
high’ bone coverage on the scaﬀold [3]. We observed nearly 100%
bone-to-implant contact on pSrBG scaﬀolds, which highlights the clin-
ical potential of pSrBG. Whether this resulted from enhanced osteo-
conductive properties or an osteoinductive eﬀect, and what the con-
tribution is of pSrBG's composition vs. its structural characteristics, such
as its macro- and micro-porosities and surface roughness, and its
packing density within the defect [3,4] remains diﬃcult to determine.
With the lack of commercially available (gold-standard) amorphous BG
controls with similar porous structure to pSrBG, it remains challenging
to investigate independently the inﬂuence of each of these parameters
on the results obtained. However, it is evident that both composition
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and porosity are expected to play an important role in the scaﬀold
tissue regeneration properties, as well as in the material's fate (e.g.
dissolution kinetics, etc.), further emphasizing the beneﬁt of producing
amorphous BGs as 3D porous scaﬀolds that are able to modify their
local ionic environment by releasing ions with therapeutic properties
upon implantation.
Besides describing the development and high osteoconductive
properties of pSrBG in a large animal model, this work also demon-
strated the beneﬁt of performing a thorough multi-scale analysis of the
bone/material interface. Our comprehensive investigation not only
showed that pSrBG allowed for the regeneration of high quality bone
and had a very small risk of systemic eﬀects, but it also provided in-
formation regarding strontium release kinetics and localization, and
highlighted diﬀerences between the two implanted scaﬀolds in terms of
material's fate and bone/material interface, showing a strong inﬂuence
of the scaﬀold type on the characteristics of the tissue that is newly-
deposited at the implant surface. These ﬁndings support the relevance
of investigating the bone material/interface and the tissue and material
physico-chemical characteristics when assessing material outcomes,
especially when considering inorganic materials that dynamically in-
teract with the local microenvironment, resulting in partial dissolution,
modiﬁcation of local ionic concentrations and important and rapid
changes in materials surface properties.
In summary, we have developed a 3D porous strontium-containing
bioactive glass that retains its amorphous phase and allows a sustained
release of strontium in vitro and in vivo, and demonstrated it out-
performed BG45S5 with regards to bone-to-material contact in a critical
sized-defect in a large animal model. Our in-depth analysis of the bone
and material characteristics following implantation showed the newly-
formed bone displayed a physiological matrix composition that con-
tained a small amount of strontium, and identiﬁed unexpected diﬀer-
ences in bone structural architecture at the macro- and micro-scales
between BG45S5 and pSrBG, with pSrBG promoting the formation of a
more mature-like lamellar bone, rather than woven bone. This study
shows pSrBG's potential as a future treatment for clinically diﬃcult
bone defects and demonstrates the utility of adopting a thorough
multiscale materials-based characterization approach when in-
vestigating bone substitute performances.
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